Cannabis Science to Host Black Tie, Red Carpet Event in Los Angeles: "Cannabis Kills Cancer," a Celebratory Fundraiser Dinner Event for Celebrities, Scientists, Doctors, Patients, and Loyalty Shareholders Alike
COLORADO SPRINGS, CO--(Marketwired - Jun 10, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicine, to host "black tie, red carpet" event in Los Angeles. Company officials state the gala is a celebratory fundraising event, "Cannabis Kills Cancer." Celebrities and Shareholders alike will join in on this unparalleled occasion to raise money for targeted cancer treatments using cannabinoids and unprecedented drug development expansions.
CBIS through its international relationships will bring several well-known celebrities to headline the affair. Including star-studded performances, renowned athletes, medical guest speakers on drug development progress, patient testimonials, and ground breaking lab reports sharing the latest results on cannabinoids and cancer.
"This should be billed as 'The Event of the Year' as this superlative gala hosted by CBIS will highlight the need for more research and development and will focus on fundraising to benefit with the battle of killing cancer. Coined, 'Cannabis Kills Cancer.' Recognition and loyalty gift announcements will be made at the Event. Shareholders who have submitted their 'loyalty gift forms' will be pleased to know that the team has continued working tirelessly, brought on extra help, and is nearing the final process of the thousands of forms received. We are elated that our shareholders are as excited as we are; as it pertains to their gift, your patience is greatly appreciated as I'm sure you can imagine there is a lot to go through one by one. Giving Thanks and recognition to our shareholders at the Event is one of our top priorities," stated Raymond C. Dabney President & CEO, Co-Founder, Cannabis Science Inc.
The Event will be highlighted by a briefing of our recent successful South Africa Trip. While the work continues in the processing aspect the goal is to tie the Cannabis Kills Cancer event with shareholders and the gift from Mr. Dabney together. "Nothing would please me more than to be able to shake every shareholder's hand and thank them for their support personally," said Mr. Dabney.
"The Event will be memorable. We will follow up shortly with announcements of the complete structure and program highlights. All our associates and partners will be using their resources to assist us in creating a most successful and effective fund raising event, highlighting the venue, the food, and the atmosphere. We will come together for one common cause, to kill cancer. Hosting the event in Los Angeles leads to the availability of more celebrities, coupled with patient success stories and CBIS to share new product information from research to launches will be an additional gift to our shareholders. Cannabis Science, and specifically myself, have been shown nothing but respect and gratitude for our efforts in the field of medical cannabis. We truly do have the best shareholders and we plan to expand that base and our successes dramatically with this type of event," concluded Mr. Dabney.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.